Hims & Hers (HIMS) Climbs 12.5% as Obesity Market Momentum Builds

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants.

Hims & Hers rallied by 12.49 percent on Monday to finish at $30.17 apiece, as investors cheered rosy growth prospects for the obesity market, alongside its efforts to bridge the gap between the rapidly increasing demand for weight-loss care and the limited capacity of traditional healthcare systems to serve it at scale.

In a health summit conducted last week, Hims & Hers Health Inc. (NYSE:HIMS) Chief Medical Officer Craig Primack highlighted the strong need for obesity to be treated with the same urgency as other chronic diseases.

Photo by Mizuno K on Pexels

“[Around] 64 percent of UK adults are overweight or living with obesity, but NHS specialist weight management services are so overwhelmed that waiting lists have closed entirely across multiple regions, and where services remain open, the average wait is two to three years. This isn’t a UK-specific problem. Traditional health systems around the world, the US included, were not designed to absorb this level of demand,” Primack underscored.

“What we’ve built at Hims & Hers helps remove that friction. Medication, nutritional coaching, activity guidance, and clinical support, all in one place, on the patient’s schedule. Those aren’t small details. They’re what can turn a treatment plan into a lasting outcome,” he noted.

Hims & Hers Health Inc. (NYSE:HIMS) currently offers FDA-approved obesity and weight loss treatments, Wegovy and Ozempic, under an ongoing partnership with Novo Nordisk.

“The gap between the scale of the obesity epidemic and the capacity of traditional care systems is not closing on its own. Closing it will require clinical rigor, genuine accessibility, and the kind of sustained support that keeps patients in treatment long enough for it to change their lives. That is what Hims & Hers is building,” Primack said.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.